Answers are grounded in this paper and cite their sources.
: Granulocyte colony-stimulating factor (G-CSF) is generally used for peripheral blood stem cell (PBSC) mobilization. However, poor mobilization is observed in patients in whom G-CSF is ineffective. Recently, plerixafor, which mo-bilizes significant amounts of PBSC into the circulation, has been used to mobilize PBSCs for autologous transplanta-tion. To select patients requiring the use of plerixafor, we aimed to predict poor PBSC mobilization using hematopoietic progenitor cell (HPC) counts measured by the XN-9000 automated hematology analyzer (Sysmex) the day before harvest. Thirty-four patients were administered G-CSF or G-CSF plus chemotherapy for mobilization, and the HPC count was measured the day before harvest (preHPC). Patients were divided into 4 groups based on their preHPC lev-els: (i) 0-5/ μ l (n=8), (ii) 6-10/ μ l (n=7), (iii) 11-20/ μ l (n=6), and (iv) > 21/ μ l (n=13). The proportion with poor mobilization in the groups was 25%, 14%, 0%, and 0%, respectively. Moreover, sufficient PBSCs could not be harvested from several patients with preHPC (cid:2) 20/ μ l. Therefore, we concluded that patients with preHPC (cid:2) 20/ μ l may potentially show poor mobilization, and patients with preHPC (cid:2) 10/ μ l had a higher probability of showing poor mobilization.
No takes yet. Share an insight, caveat, or question.
Masuda et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: